IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC

被引：49
|
作者：
Zhou, C. [1 ]
Das Thakur, M. [2 ]
Srivastava, M. K. [2 ]
Zou, W. [3 ]
Xu, H. [4 ]
Ballinger, M. [5 ]
Felip, E. [6 ]
Wakelee, H. [7 ]
Altorki, N. K. [8 ]
Reck, M. [9 ]
Liersch, R. [10 ]
Kryzhanivska, A. [11 ]
Harada, M. [12 ]
Tanaka, H. [13 ]
Hamm, J. [14 ]
McCune, S. [15 ]
McNally, V. [16 ]
Bennett, E. [5 ]
Gitlitz, B. [17 ]
Novello, S. [18 ]
机构：
[1] Tongji Univ, Dept Med Oncol, Affiliated Shanghai Pulm Hosp, Shanghai, Peoples R China
[2] Genentech Inc, Oncol Biomarker Dev, San Francisco, CA 94080 USA
[3] Genentech Inc, Prod Dev Data Sci, San Francisco, CA 94080 USA
[4] F Hoffmann La Roche Ltd, Prod Dev Data Sci, Mississauga, ON, Canada
[5] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
[6] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Oncol, Barcelona, Spain
[7] Stanford Univ, Sch Med, Med Oncol, Stanford Canc Inst, Stanford, CA 94305 USA
[8] NewYork Presbyterian Hosp, Weill Cornell Med, Cardiothorac Surg, New York, NY USA
[9] German Ctr Lung Res, Airway Res Ctr North, Lung Clin Grosshansdorf, Thorac Oncol, Grosshansdorf, Germany
[10] Clemenshosp Munster, Oncol, Munster, Germany
[11] Ivano Frankivsk Natl Med Univ, Gynecol Surg Dept, Ivano Frankivsk, Ukraine
[12] Hokkaido Canc Ctr, Resp Med, Sapporo, Hokkaido, Japan
[13] Niigata Canc Ctr Hosp, Dept Internal Med, Niigata, Japan
[14] Norton Canc Inst, Med Oncol, Louisville, KY USA
[15] Northwest Georgia Oncol Ctr, Res, Marietta, GA USA
[16] Roche Prod Ltd, Clin Dev, Welwyn Garden City, Herts, England
[17] Genentech Inc, Prod Dev, San Francisco, CA 94080 USA
[18] Univ Turin, Oncol, AOU San Luigi Gonzaga, Orbassano, Italy
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.10.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
20
引用
收藏
页码：S1374 / S1374
页数：1
相关论文
共 30 条
  • [21] IMpower010 5-y Subgroup Analysis and Relapse Patterns: Phase 3 Study of Atezolizumab vs BSC in Stage II-IIIA NSCLC
    Felip, E.
    Wakelee, H. A.
    Vallieres, E.
    Martinez-Marti, A.
    Goloborodko, O.
    Zhou, C.
    Rittmeyer, A.
    Chella, A.
    Reck, M.
    Csoszi, T.
    Bondarenko, I.
    Kenmotsu, H.
    Schutte, W.
    Ding, B.
    Zhu, Q.
    Ballinger, M.
    Bennett, E.
    Gitlitz, B. J.
    Altorki, N.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S8 - S9
  • [22] Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial (vol 398, pg 1344, 2021)
    Felip, Enriqueta
    Altorki, Nasser
    Zhou, Caicun
    Csoszi, Tibor
    Vynnychenko, Ihor
    Goloborodko, Oleksandr
    Luft, Alexander
    Akopov, Andrey
    Martinez-Marti, Alex
    Kenmotsu, Hirotsugu
    Chen, Yuh-Min
    Chella, Antonio
    Sugawara, Shunichi
    Voong, David
    Wu, Fan
    Yi, Jing
    Deng, Yu
    McCleland, Mark
    Bennett, Elizabeth
    Gitlitz, Barbara
    Wakelee, Heather
    LANCET, 2021, 398 (10312): : 1686 - 1686
  • [23] Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial
    Felip, E.
    Altorki, N.
    Zhou, C.
    Vallieres, E.
    Martinez-Marti, A.
    Rittmeyer, A.
    Chella, A.
    Reck, M.
    Goloborodko, O.
    Huang, M.
    Belleli, R.
    McNally, V.
    Srivastava, M. K.
    Bennett, E.
    Gitlitz, B. J.
    Wakelee, H. A.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 907 - 919
  • [24] Safety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage II-IIIA non-small cell lung cancer in the randomized phase III IMpower010 trial
    Lee, Jay M.
    Vallieres, Eric
    Ding, Beiying
    Johnson, Ann
    Bhagwakar, Jan
    Rashidi, Sanam
    Zhu, Qian
    Gitlitz, Barbara J.
    Weksler, Benny
    Costas, Kimberly
    Altorki, Nasser
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2023, 166 (03):
  • [25] ALINA: a phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB-IIIA anaplastic lymphoma kinase-positive (ALK +) non-small cell cancer (NSCLC)
    Rittmeyer, A.
    Solomon, B.
    Ahn, J. S.
    Barlesi, F.
    Dziadziuszko, R.
    Nishio, M.
    Shaw, A.
    Bordogna, W.
    Meyenberg, C.
    Wu, Y. L.
    PNEUMOLOGIE, 2020, 74 : S129 - S130
  • [26] IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC
    Spigel, D.
    de Marinis, F.
    Giaccone, G.
    Reinmuth, N.
    Vergnenegre, A.
    Barrios, C. H.
    Morise, M.
    Felip, E.
    Andric, Z. G.
    Geater, S.
    Ozguroglu, M.
    Mocci, S.
    McCleland, M.
    Enquist, I.
    Komatsubara, K. M.
    Deng, Y.
    Kuriki, H.
    Wen, X.
    Jassem, J.
    Herbst, R. S.
    ANNALS OF ONCOLOGY, 2019, 30 : 915 - 915
  • [27] IMPOWER110: INTERIM OVERALL SURVIVAL (OS) ANALYSIS OF A PHASE III STUDY OF ATEZOLIZUMAB (ATEZO) MONOTHERAPY VS PLATINUM-BASED CHEMOTHERAPY (CHEMO) AS FIRST-LINE (1L) TREATMENT IN PD-L1-SELECTED NSCLC
    Herbst, Roy
    De Marinis, Filippo
    Giaccone, Giuseppe
    Reinmuth, Niels
    Vergnenegre, Alain
    Barrios, Carlos
    Morise, Masahiro
    Font, Enriqueta
    Andric, Zoran
    Geater, Sarayut
    Ozguroglu, Mustafa
    Mocci, Simonetta
    McCleland, Mark
    Enquist, Ida
    Komatsubara, Kim
    Deng, Yu
    Kuriki, Hiroshi
    Wen, Xiaohui
    Jassem, Jacek
    Spigel, David
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A1 - A1
  • [28] ISEL: a Phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small-cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens
    Thatcher, N
    Chang, A
    Parikh, P
    Pemberton, K
    Archer, V
    LUNG CANCER, 2005, 49 : S4 - S4
  • [29] Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy
    Goldman, Jonathan W.
    Shi, Peipei
    Reck, Martin
    Paz-Ares, Luis
    Koustenis, Andrew
    Hurt, Karla C.
    CLINICAL LUNG CANCER, 2016, 17 (01) : 80 - 84
  • [30] Adjuvant chemotherapy with oxaliplatin/5-fluorouracil/leucovorin (FOLFOX) versus 5-fluorouracil/leucovorin (FL) for rectal cancer patients whose postoperative yp stage 2 or 3 after preoperative chemoradiotherapy: Updated results of 3-year disease-free survival from a randomized phase II study (The ADORE).
    Hong, Yong Sang
    Nam, Byung-Ho
    Kim, Kyu-Pyo
    Lee, Jae-Lyun
    Park, Joon Oh
    Park, Young Suk
    Kim, Sun Young
    Kim, Tae-You
    Kim, Jee Hyun
    Ahn, Joong Bae
    Jung, Kyung Hae
    Kim, Tae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
123